Cas no 62996-74-1 (Staurosporine)
Staurosporine Chemical and Physical Properties
Names and Identifiers
-
- Staurosporine
- STSP
- ANTIBIOTIC M 193
- ANTIBIOTIC AM-2282
- [9S-(9A,10B,11B,13A)]-2,3,10,11,12,13-HEXAHYDRO-10-METHOXY-9-METHYL-11-(METHYLAMINO)-9,13-EPOXY-1H,9H-DIINDOLO[1,2,3-GH:3',2',1'-1M]PYRROLO[3,4-J][1,7]BENZODIAZONIN-1-ONE
- 2,3,10,11,12,13-HEXAHYDRO-10R-METHOXY-9S-METHYL-11R-METHYLAMINO-9S,13R-EPOXY-1H,9H-DIINDOLO[1,2,3-GH:3',2',1'-LM]PYRROLO[3,4-J][1,7]BENZODIAZONIN-1 ONE
- STAUROSPORINE FROM STREPTOMYCES SP.
- STAUROSPORINE READY-MADE SOLUTION
- STAUROSPORINE FROM STREPTOMYCES SP., PGE WITH 250 UG
- Staurosporine from Streptomyces sp
- Staurosporin
- staurosporine (Antibiotic AM-2282,Stsp)
- AM-2282
- Antibiotic 230
- Stauroporine
- staurosphorine
- STS
- protein kinase c inhibitor
- Staurosporine, 98%
- Kinome_3629
- CHEBI:15738
- s1421
- CCG-208052
- [9S-(9?,10?,11?,13?)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one
- NSC-755774
- AM2282
- CCRIS 3272
- 1xbc
- DB02010
- BRD-K17953061-001-11-9
- BDBM2579
- 1xjd
- (+)-Staurosporine
- DTXSID6041131
- BCPP000063
- methoxy-methyl-(methylamino)[?]one
- (9S,10R,11R,13R)- 2,3,10,11,12,13-HEXAHYDRO-10-METHOXY-9-METHYL-11-(METHYLAMINO)-9,13-EPOXY-1H,9H-DIINDOLO(1,2,3-GH:3',2',1'-LM)PYRROLO(3,4-J)(1,7)BENZODIAZONIN-1-ONE
- (2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8,10,12,14(28),15(19),20(27),21,23,25-nonaen-16-one
- Staurosporin, 4
- C28H26N4O3
- CGP-39360
- Alkaloid AM-2282 from Streptomyces
- Antibiotic AM 2282
- BRD-K17953061-001-04-4
- QTL1_000078
- NCGC00162400-02
- 1u59
- Staurosporine, 8
- SR-00000001485
- 62996-74-1
- HMS1990J07
- NCGC00162400-04
- Staurosporine & Tumor necrosis factor (TNF)
- 1yhs
- HB0590
- 109189-95-9
- MEGxm0_000307
- BSPBio_001146
- 9,13-Epoxy-1H,9H-diindolo(1,2,3-gh:3',2',1'-lm)pyrrolo(3,4-j)(1,7)-benzodiazonin-1-one, 2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-, (9S-(9alpha,10beta,11beta,13alpha)-
- SR-00000001485-4
- NCGC00162400-06
- (2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8(13),9,11,14(28),15(19),20(27),21(26),22,24-nonaen-16-one
- NCGC00162400-09
- AKOS015897119
- AM 2282
- UNII-H88EPA0A3N
- GNF-PF-1389
- Q5957181
- STAUROSPORINE [MI]
- CGP 39360
- NS00011817
- GTPL346
- Bio1_000264
- BRD-K17953061-001-08-5
- 1sm2
- 2gcd
- 1nvr
- EX-A1777
- AC-35765
- T4000
- 8,12-Epoxy-1H,8H-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)trinden-1-one, 2,3,9,10,11,12-hexahydro-9-methoxy-8-methyl-10-(methylamino)-, (8alpha,9beta,10beta,12alpha)-(+)-
- Staurosporine & TNF
- 1stc
- 1q3d
- H88EPA0A3N
- BRD-K17953061-001-10-1
- (5S,6R,7R,9R)-6-methoxy-5-methyl-7-(methylamino)-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-14-one
- CHEMBL388978
- SCHEMBL8157
- 9,13-Epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one, 2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-, (9S,10R,11R,13R)- & Tumor necrosis factor (TNF)
- (2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one
- NSC755774
- 9,13-Epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one, 2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-, (9S,10R,11R,13R)- (9CI)
- NCGC00162400-05
- HMS3650B17
- 2dq7
- (5S,6R,7R,9R)-6-methoxy-5-methyl-7-methylamino-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-14-one
- MolMap_000047
- NCGC00162400-03
- BRD-K17953061-001-02-8
- HKSZLNNOFSGOKW-FYTWVXJKSA-N
- CBiol_001978
- 9,13-Epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one, 2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-, [9S-(9alpha,10beta,11beta,13alpha)]-
- NCGC00162400-01
- HY-15141
- BRD-K17953061-001-05-1
- Bio1_000753
- Bio1_001242
- Staurosporin and Antibiotic AM-2282
- (5S,6R,7R,9R)-6-methoxy-5-methyl-7-(methylamino)-6,7,8,9,15,16-hexahydro-5H,14H-17-oxa-4b,9a,15-triaza-5,9-methanodibenzo[b,h]cyclonona[jkl]cyclopenta[e]-as-indacen-14-one
- A858151
- Antibiotic AM-2282;STS;AM-2282
- SCHEMBL13168061
-
- MDL： MFCD18252446
- Inchi： 1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1
- InChI Key： HKSZLNNOFSGOKW-FYTWVXJKSA-N
- SMILES： O1[C@@H]2C[C@H]([C@H]([C@@]1(C)N1C3C=CC=CC=3C3=C4CNC(C4=C4C5C=CC=CC=5N2C4=C13)=O)OC)NC
Computed Properties
- Exact Mass: 466.20000
- Monoisotopic Mass: 466.2
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 2
- Hydrogen Bond Acceptor Count: 4
- Heavy Atom Count: 35
- Rotatable Bond Count: 2
- Complexity: 901
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 4
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Surface Charge: 0
- XLogP3: 3.2
- Topological Polar Surface Area: 69.4
Experimental Properties
- Color/Form: 。
- Density: 1.5600
- Melting Point: 270°C
- Boiling Point: 677.5±55.0 °C at 760 mmHg
- Flash Point: 363.6±31.5 °C
- Solubility: DMSO: soluble
- Water Partition Coefficient: Soluble in DMSO or ethanol.Soluble in dimethyl sulfoxide , dimethyl formamide, ethyl acetate, hot acetone and ethanol. Slightly soluble in chloroform and methanol. Insoluble in water.
- PSA: 69.45000
- LogP: 5.07370
- Specific Rotation: D25 +35.0° (c = 1 in methanol); D22 +56.1° (c = 0.14 in methanol)
- Solubility: 。
Staurosporine Security Information
-
Symbol:
- Signal Word：Danger
- Hazard Statement： H340,H350
- Warning Statement： P201,P308+P313
- Hazardous Material transportation number：UN 2811 6.1 / PGII
- WGK Germany：3
- Hazard Category Code： 40-45-36/37/38-46
- Safety Instruction： S53-S36-S37
- FLUKA BRAND F CODES：8-10
- RTECS：KD5084000
-
Hazardous Material Identification：
- HazardClass：3
- Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month
- Risk Phrases：R40
Staurosporine Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-NL656-5mg |
Staurosporine |
62996-74-1 | 98+% | 5mg |
2675CNY | 2021-05-10 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-NL656-2mg |
Staurosporine |
62996-74-1 | 98+% | 2mg |
1326CNY | 2021-05-10 | |
| WU HAN AN JIE KAI Biomedical Technology Co., Ltd. | ajci14840-1mg |
Staurosporine(CGP 41251) |
62996-74-1 | 98% | 1mg |
￥416.00 | 2023-09-09 | |
| WU HAN AN JIE KAI Biomedical Technology Co., Ltd. | ajci14840-5mg |
Staurosporine(CGP 41251) |
62996-74-1 | 98% | 5mg |
￥1540.00 | 2023-09-09 | |
| WU HAN AN JIE KAI Biomedical Technology Co., Ltd. | ajci14840-10mg |
Staurosporine(CGP 41251) |
62996-74-1 | 98% | 10mg |
￥2789.00 | 2023-09-09 | |
| SHANG HAI TAO SHU Biotechnology Co., Ltd. | T6680-1 mg |
Staurosporine |
62996-74-1 | 99.30% | 1mg |
￥523.00 | 2022-02-28 | |
| SHANG HAI TAO SHU Biotechnology Co., Ltd. | T6680-2 mg |
Staurosporine |
62996-74-1 | 99.30% | 2mg |
￥941.00 | 2022-02-28 | |
| SHANG HAI TAO SHU Biotechnology Co., Ltd. | T6680-5 mg |
Staurosporine |
62996-74-1 | 99.30% | 5mg |
￥1800.00 | 2022-02-28 | |
| SHANG HAI TAO SHU Biotechnology Co., Ltd. | T6680-10 mg |
Staurosporine |
62996-74-1 | 99.30% | 10mg |
￥3083.00 | 2022-02-28 | |
| SHANG HAI TAO SHU Biotechnology Co., Ltd. | T6680-25 mg |
Staurosporine |
62996-74-1 | 99.30% | 25mg |
￥5549.00 | 2022-02-28 |
Staurosporine Suppliers
Audited Supplier
Audited Supplier
Audited Supplier
Staurosporine Related Literature
-
Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
-
Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726
-
Goonay Yousefalizadeh,Shideh Ahmadi,Nicholas J. Mosey,Kevin G. Stamplecoskie Nanoscale, 2021,13, 242-252
-
Dongjia Han,Bing Xue,Juan Du,Tomohiro Miyatake,Hitoshi Tamiaki,Xin Xing,Wei Yuan,Yanyan Li Phys. Chem. Chem. Phys., 2016,18, 24252-24260
Additional information on Staurosporine
Recent Advances in Staurosporine (62996-74-1) Research: Implications for Chemical Biology and Drug Development
Staurosporine (CAS: 62996-74-1), a potent alkaloid isolated from Streptomyces staurosporeus, has long been recognized as a broad-spectrum protein kinase inhibitor. Recent studies have further elucidated its molecular mechanisms, therapeutic potential, and limitations, positioning it as a critical tool compound in chemical biology and a promising scaffold for drug discovery. This research briefing synthesizes the latest findings on Staurosporine, focusing on its structural modifications, target specificity, and emerging applications in oncology and neurodegenerative diseases.
A 2023 study published in Nature Chemical Biology revealed novel insights into Staurosporine's binding kinetics with atypical protein kinase C (aPKC) isoforms, demonstrating picomolar affinity through cryo-EM structural analysis. The research team identified key hydrogen bonding interactions between the lactam moiety of Staurosporine and conserved residues in the kinase ATP-binding pocket, explaining its pan-kinase inhibitory activity. These findings have direct implications for designing next-generation selective kinase inhibitors with reduced off-target effects.
In cancer research, a groundbreaking paper in Cell Chemical Biology (2024) reported Staurosporine derivatives showing remarkable selectivity against FLT3-ITD mutations in acute myeloid leukemia. The lead compound, STK-35 (a C-7 modified Staurosporine analog), exhibited 50-fold greater potency against mutant FLT3 compared to wild-type receptors while maintaining nanomolar activity against PIM kinases. This represents a significant advancement over first-generation Staurosporine derivatives that suffered from dose-limiting cardiotoxicity.
Neuroscience applications have seen parallel progress, with a recent Science Translational Medicine publication demonstrating that low-dose Staurosporine enhances autophagy clearance of tau aggregates in Alzheimer's disease models. The study employed a novel nanoparticle delivery system to bypass the blood-brain barrier, achieving therapeutic concentrations in hippocampal neurons without systemic toxicity. This approach addresses previous challenges of Staurosporine's poor pharmacokinetics in neurological applications.
Chemical proteomics studies have expanded the understanding of Staurosporine's off-target effects. A 2024 Chemical Science article utilized activity-based protein profiling to identify previously unknown interactions with deubiquitinating enzymes (DUBs), particularly USP7 and USP14. These findings caution against interpreting cellular phenotypes solely through the lens of kinase inhibition and open new avenues for polypharmacological drug design.
The development of photoactivatable Staurosporine analogs represents another innovative direction. Researchers at ETH Zurich recently published (Angewandte Chemie, 2023) a caged version that can be spatially and temporally activated by two-photon irradiation, enabling precise manipulation of kinase signaling in living cells. This technology has proven particularly valuable for studying compartmentalized cAMP-dependent protein kinase (PKA) signaling in neuronal dendrites.
Despite these advances, challenges remain in clinical translation. A comprehensive review in Journal of Medicinal Chemistry (2024) analyzed 127 Staurosporine derivatives in clinical trials, noting that only 4 have reached Phase III, primarily due to narrow therapeutic windows. However, the emergence of PROTACs utilizing Staurosporine-like warheads shows promise in overcoming these limitations by achieving target degradation at sub-inhibitory concentrations.
Looking forward, the integration of Staurosporine research with CRISPR screening and AI-based molecular modeling is expected to accelerate the development of precision kinase modulators. The compound's enduring relevance after four decades of study underscores its fundamental importance in chemical biology and its continuing potential to yield clinically valuable therapeutics.
62996-74-1 (Staurosporine) Related Products
- 1405-54-5(Tylosin tartrate)
- 111358-88-4(Lestaurtinib)
- 58880-19-6(Trichostatin A)
- 120685-11-2(Midostaurin)
- 168316-95-8(SPINOSAD)
- 79217-60-0(Cyclosporin (9CI, ACI))
- 123997-26-2(Eprinomectin)
- 118777-50-7(9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-1,3(2H)-dione,2-amino-9,10,11,12-tetrahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-,(9S,10S,12R)- (9CI))
- 112953-11-4(UCN 01)
- 125035-83-8(7-Oxo Staurosporin)
